KR101196096B1 - Method for stabilizing alpha-lipoic acid - Google Patents

Method for stabilizing alpha-lipoic acid Download PDF

Info

Publication number
KR101196096B1
KR101196096B1 KR1020120001694A KR20120001694A KR101196096B1 KR 101196096 B1 KR101196096 B1 KR 101196096B1 KR 1020120001694 A KR1020120001694 A KR 1020120001694A KR 20120001694 A KR20120001694 A KR 20120001694A KR 101196096 B1 KR101196096 B1 KR 101196096B1
Authority
KR
South Korea
Prior art keywords
lipoic acid
cyclodextrin
alpha
cosmetic composition
alpha lipoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020120001694A
Other languages
Korean (ko)
Inventor
이유리
천종우
전지민
손지현
장수진
유지은
Original Assignee
(주)에이씨티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)에이씨티 filed Critical (주)에이씨티
Priority to KR1020120001694A priority Critical patent/KR101196096B1/en
Application granted granted Critical
Publication of KR101196096B1 publication Critical patent/KR101196096B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/738Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706Algae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52Stabilizers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

PURPOSE: A cosmetic composition containing stabilized alpha-lipoic acid is provided to enhance skin whitening function. CONSTITUTION: A method for stabilizing alpha-lipoic acid comprises: a step of putting hydroxypropyl beta-cyclodextrin to water as a solvent and heating at 60-80 Deg. C.; a step of putting alpha-lipoic acid to the mixture and mixing at 50-60 Deg. C.; a step of adding Tremella Fuciformis extract to the mixture; and a step of adjusting pH of the mixture by 7.0-9.0. [Reference numerals] (AA) Embodiment 3 cosmetic composition; (BB) Initial phase; (CC) 2 weeks; (DD) 4 weeks; (EE) 8 weeks; (FF) 12 weeks

Description

알파리포산의 안정화방법{Method for stabilizing alpha-lipoic acid}Method for stabilizing alpha lipoic acid {Method for stabilizing alpha-lipoic acid}

본 발명은 알파리포산을 안정화시켜 화장료에 이용하는 기술에 관한 것으로서 항산화활성, 피부미백활성을 가지는 알파리포산을 효과적으로 이용하는 기술에 관한 것이다.The present invention relates to a technique for stabilizing alpha lipoic acid to be used in cosmetics, and a technique for effectively using alpha lipoic acid having antioxidant activity and skin lightening activity.

알파리포산(Thioctic acid, 알파 리포산, Alpha Lipoic acid, α-Lipoic acid)은 항산화제, 각질제거제, 항염증제로서 주목받고 있는 성분으로서, 식품 분야에서는 오래 전부터 널리 사용되어 온 항산화제이다. 1951년에 항산화 효과있음이 처음 발견되었고, 생체 내에서는 탄수화물을 분해할 때 필수적인 보조효소로 작용한다. 세포의 수용성과 지용성 모두에 작용하는 항산화제이며 광범위 항산화제로 불린다.Alpha lipoic acid (Thioctic acid, alpha lipoic acid, α-Lipoic acid) is an ingredient that is attracting attention as an antioxidant, exfoliant, anti-inflammatory agent, and has been widely used in the food field for a long time. It was first discovered as an antioxidant in 1951 and acts as an essential coenzyme to break down carbohydrates in vivo. It is an antioxidant that acts on both the water-soluble and fat-soluble properties of cells and is called a broad spectrum antioxidant.

치옥틱 애씨드(Thioctic acid, 알파 리포산, Alpha Lipoic acid, α-Lipoic acid)는 탄소 8개, 황 2개를 가진 화학적 구조를 하고 있는데, 매우 안정된 형태로 피부 각질층에 흡수되어 디하이드로리포산(dihydrolipoic acid)으로 전환된다. 3% 리포산을 바르는 경우 레시틴만 바르는 경우보다 자외선 B로 생기는 홍반을 절반으로 감소시키며, 더 나아가 자유기에 의한 피부 손상과 광노화, 암발생을 줄일 수 있다고 알려져 있다.Thioctic acid (Thioctic acid, Alpha Lipoic acid, α-Lipoic acid) has a chemical structure with 8 carbons and 2 sulfurs. Is converted to). The application of 3% lipoic acid is said to reduce the erythema caused by ultraviolet B by half than by applying only lecithin, and further reduce skin damage, photoaging and cancer caused by free radicals.

다만, 알파리포산은 고체상태에서는 비교적 안정하지만, 녹는점(47.5℃) 가까이 까지 가열하거나, 수용액 상태에서는 빠르게 고무모양 또는 수지상의 중합체가 되므로 그 사용에 어려움이 있다. 이에 따라 이를 안정화시키고자 하는 연구들이 진행되어 왔다.However, alpha lipoic acid is relatively stable in a solid state, but is heated to a melting point (47.5 ° C.) or difficult to use because it quickly becomes a rubbery or dendritic polymer in an aqueous state. Accordingly, studies to stabilize this have been conducted.

대한민국특허등록 제0760148호에는 알파-리포산을 포함하는 화장료 조성물에 있어서, 알파-리포산의 안정화제로서 조성물 총 중량에 대해서 프로필렌글리콜, 글리세린, 1,3-부틸렌글리콜, 1,3-부탄디올 및 솔비톨로 이루어지는 군으로부터 선택되는 1 종 이상의 폴리올 0.1~30 중량%, 및 POE(폴리옥시에틸렌) 솔비탄 지방산 에스테르, POE 알킬 에테르(LA), POE 수소화 에스테르 오일, POE(10) 옥틸도데실 에테르, POE(15) 옥틸도데실 에테르, POE(20) 옥틸도데실 에테르, POE(30) 옥틸도데실 에테르, POE(15) 글리세릴 모노스테아레이트, POE(20) 글리세릴 모노스테아레이트, POE(25) 글리세릴 모노스테아레이트 및 POE(30) 글리세릴 모노스테아레이트로 이루어지는 군으로부터 선택되는 1 종 이상의 비이온성 계면활성제 0.01~10 중량%를 포함하는 화장료 조성물이 개시되어 있으며, 대한민국공개특허 제2009-0009217에는 알파리포산(alpha lipoic acid) 0.1 ~ 20.0중량%; 1종 이상의 아미노산 0.1 ~ 12중량%; 자체 유화특성이 있는 1종 이상의 수불용성 고분자 0.5 ~ 25.0중량%; 및 잔량으로서 물, 친수성 용매 또는 이들의 혼합물을 포함하는 것을 특징으로 하는 수분산된 알파리포산 캡슐 조성물이 개시되어 있다.Korean Patent Registration No. 0760148 describes a cosmetic composition comprising alpha-lipoic acid, which is a propylene glycol, glycerin, 1,3-butylene glycol, 1,3-butanediol and sorbitol based on the total weight of the composition as a stabilizer of alpha-lipoic acid. 0.1-30% by weight of one or more polyols selected from the group consisting of POE (polyoxyethylene) sorbitan fatty acid esters, POE alkyl ethers (LA), POE hydrogenated ester oils, POE (10) octyldodecyl ethers, POE (15) octyldodecyl ether, POE (20) octyldodecyl ether, POE (30) octyldodecyl ether, POE (15) glyceryl monostearate, POE (20) glyceryl monostearate, POE (25) A cosmetic composition comprising 0.01 to 10% by weight of at least one nonionic surfactant selected from the group consisting of glyceryl monostearate and POE (30) glyceryl monostearate is disclosed. Hanminguk Patent Publication No. 2009-0009217, the alpha-lipoic acid (alpha lipoic acid) 0.1 ~ 20.0% by weight; 0.1 to 12% by weight of one or more amino acids; 0.5-25.0 wt% of one or more water-insoluble polymers having self-emulsifying properties; And water, hydrophilic solvents or mixtures thereof as residuals.

본 발명자들은 알파리포산을 안정화시켜 화장료에 적용하기 위한 연구를 하던 중 알파리포산을 포접시켜 안정화시킬 때 천연물인 흰목이버섯추출물을 사용하는 경우 알파리포산의 안정화에 기여할 뿐아니라, 그 상승작용에 의하여 화장료의 미백활성도 향상시키는 것을 발견하여 본 발명을 완성하였다. The present inventors contribute to the stabilization of alpha lipoic acid when synthesizing the alpha lipoic acid when using the extract of natural white mushrooms when the alpha lipoic acid is included in the study while stabilizing the alpha lipoic acid, and the cosmetics by synergism The present invention has been found to improve the whitening activity of.

본 발명은 안정화된 알파리포산을 포함하는 화장료조성물을 제공하는 것을 목적으로 한다.It is an object of the present invention to provide a cosmetic composition comprising stabilized alpha lipoic acid.

또한 본 발명은 상기 안정화된 알파리포산을 함유하는 화장료조성물의 제조방법을 제공하는 것을 다른 목적으로 한다.It is another object of the present invention to provide a method for preparing a cosmetic composition containing the stabilized alpha lipoic acid.

상기 목적을 달성하기 위하여 본 발명에 따르면 알파리포산 1.0 ~ 10.0 중량%, 사이클로덱스트린 20 ~ 80 중량%, 흰목이버섯추출물 0.01 ~ 3.0 중량% 및 잔부의 용매를 포함하는 화장료조성물이 제공된다.In order to achieve the above object, according to the present invention there is provided a cosmetic composition comprising 1.0 to 10.0% by weight of alpha lipoic acid, 20 to 80% by weight of cyclodextrin, 0.01 to 3.0% by weight of Albino mushroom extract and the remainder of the solvent.

상기 사이클로덱스트린은 하이드록시프로필 베타 사이클로덱스트린, 베타 사이클로덱스틴, 알파 사이클로덱스트린, 감마 사이클로덱스트린 및 포도당으로 이루어지는 군으로부터 선택되며, 바람직하게는 하이드록시프로필 베타 사이클로덱스트린이다.The cyclodextrin is selected from the group consisting of hydroxypropyl beta cyclodextrin, beta cyclodextrin, alpha cyclodextrin, gamma cyclodextrin and glucose, preferably hydroxypropyl beta cyclodextrin.

상기 용매로는 물, 에탄올, 메탄올, 아세톤, 글리세린 및 지용성 용매로 이루어지는 군으로부터 선택되는 적어도 하나의 것이 사용될 수 있다.As the solvent, at least one selected from the group consisting of water, ethanol, methanol, acetone, glycerin, and a fat-soluble solvent may be used.

상기 화장료조성물에 비타민 C, 비타민 E, 글루타티온, 리포산, 코엔자임 Q10, 엽산, 아데노신, 알부틴 및 페룰릭 산으로 이루어지는 군으로부터 선택되는 적어도 하나의 활성성분이 더욱 포함될 수 있다.The cosmetic composition may further include at least one active ingredient selected from the group consisting of vitamin C, vitamin E, glutathione, lipoic acid, coenzyme Q10, folic acid, adenosine, arbutin and ferulic acid.

상기 다른 목적을 달성하기 위한 본 발명에 따르면According to the present invention for achieving the above another object

(A)용매에 포접체인 사이클로덱스트린을 용해시켜 혼합하는 단계;(A) dissolving and mixing the cyclodextrin as a clathrate in a solvent;

(B)알파리포산을 상기 (A)단계의 혼합물에 추가하여 혼합하는 단계;(B) adding a mixture of the aliphatic acid to the mixture of step (A);

(C)안정화제인 흰목이버섯추출물을 상기 (B)단계의 혼합물에 추가하여 혼합하는 단계; 및(C) mixing the white wood mushroom extract as a stabilizer in addition to the mixture of step (B); And

(D)상기 (C)단계의 혼합물을 pH 7.0 ~ 9.0으로 보정하는 단계를 포함하는 화장료조성물의 제조방법이 제공된다. (D) is provided a method for producing a cosmetic composition comprising the step of correcting the mixture of step (C) to pH 7.0 ~ 9.0.

알파리포산의 포접 안정화시에 흰목이버섯추출물을 첨가하는 경우에 알파리포산의 안정화에 크게 기여할 뿐 아니라, 알파리포산과의 상승작용에 의하여 흰목이버섯추출물은 화장료의 미백활성을 크게 증진시키는 효과가 있다. In addition to the stabilization of alpha lipoic acid in addition to white licorice extract during inclusion stabilization of alpha lipoic acid, the synapse with alpha lipoic acid greatly enhances the whitening activity of cosmetics. .

도 1은 본 발명의 일 실시예에 따라 제조된 화장료조성물에 대한 안정성시험결과 그래프이다.
도 2는 본 발명의 일 실시예에 따라 제조된 화장료조성물의 콜라겐 생합성 촉진효과를 나타내는 그래프이다.
1 is a graph of the stability test results for the cosmetic composition prepared according to an embodiment of the present invention.
Figure 2 is a graph showing the collagen biosynthesis promoting effect of the cosmetic composition prepared according to an embodiment of the present invention.

이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.

본 발명의 일 실시예에 따르면 알파리포산 1.0 ~ 10.0 중량%, 사이클로덱스트린 20 ~ 80 중량%, 흰목이버섯추출물 0.01 ~ 3.0 중량% 및 잔부의 용매를 포함하는 화장료조성물이 제공된다.According to an embodiment of the present invention is provided a cosmetic composition comprising 1.0 to 10.0% by weight of alpha lipoic acid, 20 to 80% by weight of cyclodextrin, 0.01 to 3.0% by weight of white fungus extract and the remainder of the solvent.

알파리포산(Alpha Lipoic acid)는 하기 화학식 1과 같은 구조를 가지는 화합물이다.Alpha Lipoic acid is a compound having a structure as shown in Formula 1 below.

[화학식 1][Formula 1]

Figure 112012001408213-pat00001
Figure 112012001408213-pat00001

항산화활성 등을 가지는 상기 알파리포산은 에탄올이나 폴리올에는 잘 용해되나 수용액 중에서는 산화되어 수지상의 중합체로 되며, 이 과정에서 악취가 발생되는 문제점이 있어 화장료의 성분으로 사용하기에 어려움이 있었다. 이에 따라 사이클로 덱스트린으로 상기 알파리포산을 포접하여 안정화시키고자 하는 것이다. 사이클로 덱스트린은 흰색의 결정 또는 결정성 가루로서 냄새가 없고 약간의 단맛이 난다. 사이클로덱스트린은 6~12개 포도당이 각각 α-1,4 글리코시드결합을 한 고리모양의 올리고당이며 α-사이클로덱스트린, β-사이클로덱스트린, γ-사이클로덱스트린으로 구분된다. 물에 잘 녹고 에탄올에 약간 녹으며 278℃에서 분해된다. 포접 기능을 가지며, 친수성과 소수성의 두 가지 성질을 모두 가지고 있다. 또한 각종 산, 알칼리에 대해 내열성을 가지며 가열이나 습도에도 강한 편이다. 베타-사이클로덱스트린의 공동의 직경은 780pm(피코미터)이고, 감마-사이클로덱스트린은 950pmm이다. 결정학적 연구에 따르면 베타-사이클로덱스트린 공동은 아다만탄 유도체들과 같은 구형 형상의 게스트 물질의 수용에 적합하며, 헤드-헤드 이량체에 의해 둘러 싸여진 공간은 단일분자의 공동에 비해 약 2.5배 더 넓다는 것이 보고되어 있다. 또한, 베타-사이클로덱스트린의 화학적 변화가 그 공동의 크기 및 형태를 변경시킨다는 것도 알려져 있다. 상기 사이클로덱스트린으로는 하이드록시프로필 베타 사이클로덱스트린, 베타 사이클로덱스틴, 알파 사이클로덱스트린, 감마 사이클로덱스트린 및 포도당으로 이루어지는 군으로부터 선택될 수 있다. 본 발명에 있어서 알파리포산을 포접하기 위해 사용되는 사이클로덱스트린으로는 하드록시프로필 베타-사이클로덱스트린(Hydroxypropyl β-Cyclodextrin)이 바람직하다.The alpha lipoic acid having an antioxidant activity or the like is well dissolved in ethanol or polyol, but oxidized in an aqueous solution to form a dendritic polymer, and there is a problem in that odor is generated in this process, which makes it difficult to use as a component of a cosmetic. Accordingly, the alpha lipoic acid is included in the cyclodextrin to stabilize it. Cyclodextrins are white crystals or crystalline powder, odorless and slightly sweet. Cyclodextrins are ring-shaped oligosaccharides in which 6-12 glucose is α-1,4 glycoside bonded, respectively, and are classified into α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin. Soluble in water, slightly soluble in ethanol and decompose at 278 ℃. It has an inclusion function and has both hydrophilic and hydrophobic properties. In addition, it has heat resistance against various acids and alkalis and is also resistant to heating and humidity. The diameter of the cavity of the beta-cyclodextrin is 780 pm (picometer) and the gamma-cyclodextrin is 950 pmm. Crystallographic studies have shown that beta-cyclodextrin cavities are suitable for the reception of spherical shaped guest materials such as adamantane derivatives, with the space enclosed by the head-head dimer being about 2.5 times more than the cavities of single molecules. It is reported that it is wide. It is also known that chemical changes in beta-cyclodextrin alter the size and shape of the cavity. The cyclodextrin may be selected from the group consisting of hydroxypropyl beta cyclodextrin, beta cyclodextrin, alpha cyclodextrin, gamma cyclodextrin and glucose. In the present invention, the cyclodextrin used for inclusion of alpha lipoic acid is preferably hydroxypropyl beta-cyclodextrin (Hydroxypropyl β-Cyclodextrin).

상기 흰목이버섯추출물을 첨가함으로써 알파리포산의 안정성이 크게 향상된다. 흰목이버섯(Tremella fuciformis)은 식용버섯으로 이용되어 왔다. 최근에는 흰목이 버섯의 자실체로부터 얻은 여러 다당류의 화학구조가 밝혀져 있으며, 흰목이 버섯 자실체의 다당류 단편은 많은 생리학적 활성을 보이는 것으로 알려져 있다. 본 발명에 있어서, 사용되는 흰목이버섯추출물은 이러한 흰목이버섯을 추출한 것으로서, 구체적으로는 자실체에서 추출한 버섯다당체에 해당하며 그 추출방법은 제한적이지 않다. The stability of alpha lipoic acid is greatly improved by adding the cedar mushroom extract. Tremella fuciformis has been used as an edible mushroom. Recently, the chemical structure of several polysaccharides obtained from the fruiting body of the white-necked mushroom has been revealed, and the polysaccharide fragments of the mushroom fruiting body of the white-necked tree are known to exhibit many physiological activities. In the present invention, the cedar mushroom extract used is extracted from the cedar mushroom, specifically, the mushroom polysaccharide extracted from the fruiting body and the extraction method is not limited.

상기 용매로는 물, 에탄올, 메탄올, 아세톤, 글리세린 및 지용성 용매로 이루어지는 군으로부터 선택되는 적어도 하나의 것이 사용될 수 있다.As the solvent, at least one selected from the group consisting of water, ethanol, methanol, acetone, glycerin, and a fat-soluble solvent may be used.

상기 화장료조성물에 비타민 C, 비타민 E, 글루타티온, 리포산, 코엔자임 Q10, 엽산, 아데노신, 알부틴 및 페룰릭 산으로 이루어지는 군으로부터 선택되는 적어도 하나의 활성성분이 더욱 포함될 수 있다.The cosmetic composition may further include at least one active ingredient selected from the group consisting of vitamin C, vitamin E, glutathione, lipoic acid, coenzyme Q10, folic acid, adenosine, arbutin and ferulic acid.

상기 다른 목적을 달성하기 위한 본 발명에 따르면 (A)용매에 포접체인 사이클로덱스트린을 용해시켜 혼합하는 단계; (B)알파리포산을 상기 (A)단계의 혼합물에 추가하여 혼합하는 단계; (C) 안정화제인 흰목이버섯추출물을 상기 (B)단계의 혼합물에 추가하여 혼합하는 단계; 및 (D)상기 (C)단계의 혼합물을 pH 7.0 ~ 9.0으로 보정하는 단계를 포함하는 화장료조성물의 제조방법이 제공된다.According to the present invention for achieving the above another object (A) dissolving and mixing the cyclodextrin as a clathrate in a solvent; (B) adding a mixture of the aliphatic acid to the mixture of step (A); (C) mixing the white-white mushroom extract as a stabilizer in addition to the mixture of step (B); And (D) there is provided a method for producing a cosmetic composition comprising the step of correcting the mixture of step (C) to pH 7.0 ~ 9.0.

본 발명에 따른 일 구체예에 따르면 다음과 같은 방법에 의하여 안정화된 알파리포산을 함유하는 조성물을 제조할 수 있다. 용매인 정제수에 하드록시프로필 사이클로덱스트린(Hydroxypropyl Cyclodextrin)을 혼합하고 60~80℃에서 중탕가온하여 완전 용해 후, 알파 리포산을 50~60℃의 조건 하에서 추가로 투입하여 완전히 용해시킨다. 온도를 유지한 채 혼합이 마무리되면, 흰목이버섯추출물을 추가로 투입하여 완전히 혼합한다. 이때, 철, 수분, 산소와의 접촉을 최소화하여 용해시키는 것이 중요하다. 완전히 혼합이 되면, 1, 2 헥산디올(Hexanediol)을 추가로 넣어 방부활성을 부여할 수도 있다. 이어 상기 혼합물에 KOH, NaOH 용액을 추가로 투입하여 pH를 7.0~9.0으로 보정하여 제조한다. 이 후, 원하는 무게까지 감압 증류할 수 있다.According to one embodiment according to the invention it can be prepared a composition containing alpha lipoic acid stabilized by the following method. After mixing the hydroxypropyl cyclodextrin (Hydroxypropyl Cyclodextrin) in the solvent and the complete water dissolution in hot water at 60 ~ 80 ℃, alpha lipoic acid is further added under 50 ~ 60 ℃ conditions to completely dissolve. When the mixing is completed while maintaining the temperature, the white wood mushroom extract is added and mixed thoroughly. At this time, it is important to minimize the contact with iron, water, oxygen to dissolve. When completely mixed, 1, 2 hexanediol may be added to impart antiseptic activity. Subsequently, KOH, NaOH solution was added to the mixture to prepare a pH of 7.0 to 9.0. Thereafter, the product can be distilled under reduced pressure to the desired weight.

이와 같이 안정화된 알파리포산의 안정성시험결과 흰목이버섯추출물을 첨가한 경우에 그 안정성이 크게 향상되는 것을 확인할 수 있었다. 또한 상기 안정화된 알파리포산을 화장료의 제형으로 하여 시험해 본 결과 화장료의 경시안정성의 향상 뿐 아니라, 콜라겐생합성촉진효과, 멜라닌 생성억제효과등이 우수한 것으로 확인되었다. 이는 흰목이버섯추출물이 안정성향상 뿐 아니라 화장료자체의 활성에도 크게 기여한 것임을 알 수 있다.
As a result of the stability test of the stabilized alpha lipoic acid, it was confirmed that the stability was greatly improved when the mushroom extract was added. In addition, as a result of testing the stabilized alpha lipoic acid as a cosmetic formulation, it was confirmed that not only the aging stability of the cosmetic was improved, but also the collagen biosynthesis promoting effect and the melanin production inhibitory effect were excellent. It can be seen that the white-brown mushroom extract contributed greatly to the activity of the cosmetics as well as the stability.

[실시예][Example]

이하, 실시예 및 시험예를 통하여 본 발명을 더욱 상세하게 설명한다.
Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples.

실시예 1, 2:알파리포산 안정화조성물의 제조Example 1, 2: Preparation of alfalfaic acid stabilizing composition

하기의 표 1의 조성에 따라 안정화조성물을 제조하였다. 용매인 정제수에 하드록시프로필 베타 사이클로덱스트린(Hydroxypropyl β-Cyclodextrin)을 넣어 밀봉한 후 60~80℃에서 중탕가온하여 완전 용해시켰다. 완전 용해 후 알파 리포산을 50~60℃의 조건 하에서 투입하여 완전히 용해시켜 혼합하였다. 혼합이 마무리되면 흰목이버섯추출물(제품명:Tremella Fuciformis Extract, SANGHAI HUIWEN BIOTECH CO., LTD 제조)을 추가하여 완전히 혼합하였다. 완전히 혼합 후, 1, 2 헥산디올(1,2 Hexanediol)을 추가로 넣었다. 이어 상기 혼합물에 10% KOH 용액을 이용하여 pH를 조절하였다.
A stabilizing composition was prepared according to the composition of Table 1 below. Hard hydroxypropyl beta cyclodextrin (Hydroxypropyl β-Cyclodextrin) was added to the solvent and purified water, and then completely dissolved by hot water heating at 60 ~ 80 ℃. After complete dissolution, alpha lipoic acid was added under conditions of 50 to 60 ° C., completely dissolved, and mixed. After the mixing was completed, the mixture was added to the white agar mushroom extract (product name: Tremella Fuciformis Extract, manufactured by SANGHAI HUIWEN BIOTECH CO., LTD.). After complete mixing, 1,2 hexanediol (1,2 Hexanediol) was further added. The pH was then adjusted using a 10% KOH solution in the mixture.

비교예 1~5 : 알파리포산 안정화조성물의 제조Comparative Examples 1 to 5: preparation of alpha lipoic acid stabilizing composition

하기 표 1의 조성에 따라 상기 실시예와 동일한 방법으로 제조하였다.It was prepared in the same manner as in Example according to the composition of Table 1.

구분(중량%)Category (% by weight) 실시예1Example 1 실시예2Example 2 비교예1Comparative Example 1 비교예2Comparative Example 2 비교예3Comparative Example 3 비교예4Comparative Example 4 비교예5Comparative Example 5 정제수Purified water TO 100TO 100 TO 100TO 100 TO 100TO 100 TO 100TO 100 TO 100TO 100 TO 100TO 100 TO 100TO 100 하이드록시프로필 β-싸이클로덱스트린 Hydroxypropyl β-cyclodextrin 60.060.0 60.060.0 30.030.0 40.040.0 50.050.0 60.060.0 60.060.0 헥산디올Hexanediol -- 2.02.0 -- -- -- -- 2.02.0 알파리포산Alpha Lipoic Acid 5.05.0 5.05.0 5.05.0 5.05.0 5.05.0 5.05.0 5.05.0 흰목이버섯추출물White Oyster Mushroom Extract 1.01.0 1.01.0 -- -- -- -- -- pH pH 8.58.5 8.58.5 8.58.5 8.58.5 8.58.5 8.58.5 8.58.5

시험예 1:안정성 시험Test Example 1: Stability Test

상기 실시예 및 비교예에서 제조된 알파리포산 안정화조성물에 대하여 성상안정성 시험 및 함량 안정성 시험을 하였다.
The alpha-lipoic acid stabilized compositions prepared in Examples and Comparative Examples were subjected to property stability tests and content stability tests.

1.성상안정성 시험1. Property stability test

상기 실시예 및 비교예에서 제조된 알파리포산 안정화조성물에 대하여 하기 표 2의 조건에서 성상안정성시험을 하였으며, 그 결과는 표 2에 나타내었다.Properties of the alpha lipoic acid stabilized composition prepared in Examples and Comparative Examples were tested under the conditions of Table 2, and the results are shown in Table 2.

성상안정성 시험 결과Appearance stability test result 구분division 1일 후1 day later 1주 후After 1 week 2주 후after 2 weeks 4주 후After 4 weeks 8주 후8 weeks later 12주 후12 weeks later 실시예 1


Example 1


상온Room temperature
45℃45 ° C 4℃4 ℃ 차광상온Shading room temperature 실시예 2


Example 2


상온Room temperature
45℃45 ° C 4℃4 ℃ 차광상온Shading room temperature 비교예 1


Comparative Example 1


상온Room temperature
45℃45 ° C 4℃4 ℃ 차광상온Shading room temperature 비교예 2


Comparative Example 2


상온Room temperature
45℃45 ° C 4℃4 ℃ 차광상온Shading room temperature 비교예 3


Comparative Example 3


상온Room temperature
45℃45 ° C 4℃4 ℃ 차광상온Shading room temperature 비교예 4


Comparative Example 4


상온Room temperature
45℃45 ° C 4℃4 ℃ 차광상온Shading room temperature 비교예 5


Comparative Example 5


상온Room temperature
45℃45 ° C 4℃4 ℃ 차광상온Shading room temperature

(○:변화없음, ◑:약한변색, ▣:많이 변색 및 현탁, ★:완전 변색 및 침전 발생)(○: no change, ◑: weak color change, ▣: many color change and suspension, ★: complete color change and precipitation)

상기 표 2에서 확인되는 바와 같이 흰목이버섯추출물을 함유하는 실시예 1, 2의 조성물은 비교예들에 비하여 성상안정성이 우수하게 나타났다.
As confirmed in Table 2, the compositions of Examples 1 and 2, which contain white mushroom extract, were superior in phase stability as compared to the comparative examples.

2.함량안정성 시험2.Content stability test

상기 실시예 및 비교예에서 제조된 알파리포산 안정화조성물에 대하여 하기 표 3의 조건에서 함량안정성시험을 하였으며, 그 결과는 표 3에 나타내었다.The content of the alpha lipoic acid stabilizing composition prepared in Examples and Comparative Examples was tested for the content stability under the conditions of Table 3, and the results are shown in Table 3.

구분division 실시예 2Example 2 비교예 4Comparative Example 4 비교예 5Comparative Example 5 상온Room temperature 45℃45 ° C 4℃4 ℃ 차광상온Shading room temperature 상온Room temperature 45℃45 ° C 4℃4 ℃ 차광상온Shading room temperature 상온Room temperature 45℃45 ° C 4℃4 ℃ 차광상온Shading room temperature 초기Early 100100 100100 100100 100100 100100 100100 100100 100100 100100 100100 100100 100100 2주2 weeks 100100 100100 100100 100100 9191 8888 9898 9595 9595 9090 9898 9898 4주4 weeks 100100 100100 100100 100100 8686 8181 9090 8888 9191 8686 9595 9393 8주8 weeks 100100 9999 100100 100100 8080 7777 8686 8383 8686 8181 9090 8888 12주12 Weeks 9999 9797 100100 9999 7676 7272 8181 7979 8080 7878 8484 8282

상기 표 3에서 확인되는 바와 같이 흰목이버섯추출물을 함유하는 실시예 2의 조성물은 비교예들에 비하여 함량안정성이 우수하게 나타났다.
As confirmed in Table 3, the composition of Example 2 containing an extract of Albino mushroom was superior in content stability compared to the comparative examples.

실시예 3:안정화된 알파리포산을 함유하는 화장료조성물의 제조Example 3: Preparation of Cosmetic Composition Containing Stabilized Alpha Lipoic Acid

상기 실시예에서 제조된 안정화 알파리포산을 함유하는 크림을 하기 표 4의 조성에 따라 통상의 방법으로 제조하였다.Cream containing the stabilized alpha lipoic acid prepared in the above Example was prepared according to the conventional method according to the composition of Table 4.

성분ingredient 중량(g)Weight (g) 밀납Wax 2.02.0 스테아린산 모노글리세린Stearic Acid Monoglycerin 3.03.0 유동파라핀Liquid paraffin 4.04.0 폴리솔베이트Polysorbate 5.05.0 스쿠알렌Squalene 5.05.0 히알루론산Hyaluronic acid 0.30.3 라이신Lysine 0.30.3 글리세린glycerin 4.04.0 1,3 부틸렌 글리콜1,3 butylene glycol 8.08.0 안정화된 알파 리포산(실시예 2)Stabilized Alpha Lipoic Acid (Example 2) 10.010.0 향료Spices 0.0010.001 방부제antiseptic 0.30.3 정제수Purified water 58.158.1 총합total 100.0100.0

시험예 2:제형 안정성 시험Test Example 2: Formulation Stability Test

상기 실시예 3에서 제조된 화장료조성물에 대한 안정성시험을 하였다. 함량 분석방법에 따라 시험하였다. HPLC 조건은 다음과 같다.The stability test for the cosmetic composition prepared in Example 3 was carried out. It was tested according to the content analysis method. HPLC conditions are as follows.

함량 분석 (HPLC Test Methods)Content Analysis (HPLC Test Methods)

- 표 준 품: Alpha-Lipoic acid (99.29%)-Standard: Alpha-Lipoic acid (99.29%)

- 검 출 기: UV-VIS Detector ( 330 nm )-Detector: UV-VIS Detector (330 nm)

- 컬 럼: Mightysil RP-18 GP 250-4.6 ( 5 um )Column: Mightysil RP-18 GP 250-4.6 (5 um)

- 이 동 상: (MeOH:Water) + 0.1% Acetic acid / 70 : 30Mobile phase: (MeOH: Water) + 0.1% Acetic acid / 70: 30

- 유 량: 1 mL / minFlow rate: 1 mL / min

그 결과는 도 1에 나타내었다. 도 1에서 확인되는 바와 같이 시간이 경과함에 따라 그 함량에 변화가 없어 경시안정성이 우수한 것으로 확인되었다.
The results are shown in FIG. As confirmed in FIG. 1, there was no change in its content with time, and it was confirmed that time stability was excellent.

시험예 3: 콜라겐 생합성 촉진 효과시험Test Example 3: Collagen Biosynthesis Promotion Effect Test

섬유아세포를 10% FBS를 첨가한 IMDM 배지에 5×105의 세포농도로 접종하여 37℃, 5% CO2배양기에서 24시간 동안 배양하였다. 24시간 배양하여 상기 실시예 3의 흰목이버섯추출물을 포함하는 안정화 알파리포산 함유 화장료조성물을 최종 농도가 50, 100, 500, 1000㎍/㎖가 되도록 디메틸설폭시드에 희석하여 제조한 희석용액을 첨가하여 18시간 동안 동일 조건에서 배양 후 1시간 동안 UV를 조사시켜 세포에 스트레스를 주었다. 이후 Trizol reagent(invitrogen, USA)를 이용하여 섬유아세포를 회수하여 mRNA를 추출하여 일련의 과정을 거쳐 cDNA를 합성하였다. 합성된 cDNA로부터 PROCOLLAGEN TYPEⅠ유전자 부위를 증폭시켜 전기영동을 통해 유전자 발현 양을 확인하였으며, 유전자 증폭은 thermal cycler (GenePro, Hangzhou bioer tech., CHINA)를 사용하여 10x taq polymerase buffer, 10 mM dNTP, 10 pmol primer (F: AGC CAG CAG ATC GAG AAC AT, R: TCT TGT CCT TGG GGT TCT TG), taq polymerase를 혼합하고 증류수를 더하여 50 uL로 조정 후 95도 5분 1cycle/95도 1분/51도 2분/72도 1분 28 cycle 증폭, 72도에서 5분간 반응하는 조건으로 수행하였다. 생성된 procollagen의 발현율은 아래식에 따라 계산하였으며 대조구로는 시료를 처리하지 않고 UV를 조사하지 않은 정상 섬유아세포를 사용하였다. 비교예로는 흰목이버섯추출물을 포함하지 않는 비교예 5의 안정화 알파리포산을 함유하는 화장료조성물을 상기 실시예 3과 동일한 방법으로 제조하여 사용하였다.
Fibroblasts were inoculated in IMDM medium with 10% FBS at a cell concentration of 5 × 10 5 and incubated in 37 ° C., 5% CO 2 incubator for 24 hours. A dilution solution prepared by diluting the stabilized alpha-lipoic acid-containing cosmetic composition containing the white myrtle mushroom extract of Example 3 in dimethyl sulfoxide so as to have a final concentration of 50, 100, 500, and 1000 µg / ml was incubated for 24 hours. After 18 hours incubation under the same conditions was irradiated with UV for 1 hour to give a stress to the cells. Thereafter, the fibroblasts were recovered using Trizol reagent (invitrogen, USA), mRNA was extracted, and cDNA was synthesized through a series of processes. The amount of gene expression was confirmed by electrophoresis by amplifying the PROCOLLAGEN TYPE I gene region from the synthesized cDNA, and gene amplification was performed using thermal cycler (GenePro, Hangzhou bioer tech., CHINA) using 10x taq polymerase buffer, 10 mM dNTP, 10 pmol primer (F: AGC CAG CAG ATC GAG AAC AT, R: TCT TGT CCT TGG GGT TCT TG), mixed with taq polymerase and adjusted to 50 uL with distilled water 95 ° 5 min 1 cycle / 95 ° 1 min / 51 ° 2 cycles / 72 degrees 1 minutes 28 cycles amplification, was carried out under the conditions of reacting for 5 minutes at 72 degrees. The expression rate of the produced procollagen was calculated according to the following equation. As a control, normal fibroblasts without treatment of the sample and UV irradiation were used. As a comparative example, the cosmetic composition containing the stabilizing alpha lipoic acid of Comparative Example 5, which did not contain the mushroom extract, was prepared and used in the same manner as in Example 3.

procollagen 발현율(%) = B/A × 100(%)Procollagen Expression (%) = B / A × 100 (%)

A: 상기 대조군에서의 procollagen 발현 량A: amount of procollagen expression in the control group

B: 시료 처리 및 UV조사 섬유아세포의 procollagen 발현 량
B: Procollagen Expression Levels of Sample Treatment and UV Irradiated Fibroblasts

상기 시험결과를 하기의 표 5 및 도 2에 나타내었다.The test results are shown in Table 5 and FIG. 2.

시료 농도
(㎍/㎖)
Sample concentration
(Μg / ml)
procollagen 발현율(%)procollagen expression rate (%)
실시예 3 화장료조성물Example 3 Cosmetic Composition 비교예 5 화장료조성물Comparative Example 5 Cosmetic Composition concon 100.00100.00 100.0100.0 1010 100.14100.14 100.0100.0 5050 111.77111.77 106.98106.98 100100 216.62216.62 174.26174.26

상기 표 5의 결과에서 확인되는 바와 같이, 흰목이버섯추출물에 의하여 안정화된 알파 리포산함유 화장료 조성물을 적용한 시료의 함량이 증가할수록 피부 주름에 관련 있는 콜라겐 생합성을 촉진하는 효과가 더 높게 나타났다. 그 결과를 도 2에 나타내었다. 또한 상기 표 5에서 확인되는 바와 같이 흰목이버섯추출물을 함유하지 않는 비교예 5의 화장료조성물에 비하여 훨씬 우수한 효과를 나타내었다.
As can be seen from the results of Table 5, as the content of the sample to which the alpha lipoic acid-containing cosmetic composition stabilized by the fungus extract was increased, the effect of promoting collagen biosynthesis related to skin wrinkles was higher. The results are shown in FIG. In addition, as confirmed in Table 5, the white neck showed a much better effect than the cosmetic composition of Comparative Example 5 containing no mushroom extract.

시험예 4: 화장료조성물의 미백활성효과시험Experimental Example 4: Whitening Activity Test of Cosmetic Composition

1.멜라닌 생성억제 효과시험1. Melanin production inhibitory effect test

6웰 플레이트에 웰당 10% FBS를 첨가한 DMEM 배지 2㎖에 2 × 105의 농도로 B16F10 세포를 접종하여 37℃, 5% CO2배양기에서 24시간 동안 배양하였다. 24시간 배양한 후 웰을 새로운 배지로 교환하고, 상기 실시예 3의 화장료조성물을 각각 62.5, 125, 250㎍/㎖가 되도록 디메틸설폭시드에 희석하여 제조한 희석용액을 첨가하여 18시간 동안 동일 조건에서 배양하였다. 이후 PBS 세척하고 300㎕의 0.25% trypsin-EDTA로 처리하여 세포를 수집하고 마이크로센트리퓨즈 튜브로 옮긴 후, 1,000 rpm에서 4 분간 원심분리 하였다. 그 침전된 세포를 PBS로 2회 세척 후, 1N NaOH 500㎕를 넣어 멜라닌을 용해하였다. 멜라닌의 용해를 돕기 위해, 100℃에서 10분간 반응하였다. 각 마이크로센트리퓨즈 튜브의 멜라닌의 양을 400 nm에서 흡광도를 측정하여 분광계적으로 결정하였다. B16F10 cells were inoculated in 2 ml of DMEM medium added with 10% FBS per well to a 6-well plate at a concentration of 2 × 10 5 and incubated in a 37 ° C., 5% CO 2 incubator for 24 hours. After culturing for 24 hours, the wells were exchanged with fresh medium, and the diluting solution prepared by diluting the cosmetic composition of Example 3 to 62.5, 125, and 250 µg / ml, respectively, was added to the same conditions for 18 hours. Incubated at. The cells were then washed with PBS, treated with 300 μl of 0.25% trypsin-EDTA, collected and transferred to a microcentrifuge tube, and then centrifuged at 1,000 rpm for 4 minutes. The precipitated cells were washed twice with PBS, and 500 µl of 1N NaOH was added to dissolve melanin. To help dissolve melanin, the reaction was carried out at 100 ° C. for 10 minutes. The amount of melanin in each microcentrifuge tube was determined spectrophotometrically by measuring absorbance at 400 nm.

상기 시험결과 하기의 표 6과 같은 결과를 얻었다.The test results were obtained as shown in Table 6 below.

시료농도(㎍/㎖)Sample concentration (㎍ / ㎖) Melanin synthesis inhibition(%)Melanin synthesis inhibition (%) 실시예 3 화장료조성물Example 3 Cosmetic Composition 비교예 5 화장료조성물Comparative Example 5 Cosmetic Composition 00 0.00 0.00 0.000.00 1010 30.9030.90 23.1123.11 5050 37.4937.49 29.6529.65 100100 45.5345.53 37.4437.44

멜라닌 생합성 저해율(Melanin synthesis inhibition)이 클수록 멜라닌의 생성이 억제된 것 인데, 상기 표 6에서 확인되는 바와 같이 상기 실시예 3의 조성물을 처리했을 때 멜라닌 생합성 저해율이 증가하여 우수한 멜라닌 생성 억제 효과를 나타냄을 알 수 있었고, 농도가 증가함에 따라 상승적인 효과가 있음을 알 수 있었다. 또한 상기 표 6에서 확인되는 바와 같이 흰목이버섯추출물을 함유하지 않는 비교예 5의 화장료조성물에 비하여 훨씬 우수한 효과를 나타내었다.
The higher the melanin synthesis inhibition (Melanin synthesis inhibition) is the production of melanin is suppressed, as shown in Table 6 when the composition of Example 3 treated melanin biosynthesis inhibition rate shows an excellent melanin production inhibitory effect It was found that, as the concentration increases there was a synergistic effect. In addition, as shown in Table 6, the white neck showed a much better effect than the cosmetic composition of Comparative Example 5 containing no mushroom extract.

2.TRP-1, TRP-2 및 Mu-tyr발현 억제 효과시험2.TRP-1, TRP-2 and Mu-tyr expression inhibitory effect test

B16F10세포를 10% FBS를 첨가한 DMEM 배지에 5 × 105의 농도로 접종하여 37℃, 5% CO2배양기에서 24시간 동안 배양하였다. 24시간 배양하여 실시예 3에서 제조된 안정성이 증진된 알파 리포산 화장료 조성물을 각각 50, 100㎍/㎖가 되도록 디메틸설폭시드에 희석하여 제조한 희석용액을 첨가하여 18시간 동안 동일 조건에서 배양하였다. 이후 Trizol reagent(invitrogen, USA)를 이용하여 B16F10세포를 회수하여 mRNA를 추출하여 일련의 과정을 거쳐 cDNA를 합성하였다. 합성된 cDNA로부터 TRP-1(Tyrosinase related protein-1), TRP-2(Tyrosinase related protein-2), Mu-tyrosinase 유전자 부위를 증폭시켜 전기영동을 통해 유전자 발현 양을 확인하였으며, 유전자 증폭은 thermal cycler (GenePro, Hangzhou bioer tech., CHINA)를 사용하여 10x taq polymerase buffer, 10 mM dNTP, 10 pmol primer (TRP-1 F: AGG AAT CTG GCT TGG GAT TT, TRP-1 R: ATG AGC CAC AAG GGT CAG TC, TRP-2 F: AGC AGA CGG AAC ACT GGA CT, TRP-2 R: CAG GTA GGA GCA TGC TAG GC, Mu-tyr F: GGG CCC AAA TTG TAC AGA GA, Mu-tyr R: GGC AAA TCC TTC CAG TGT GT), taq polymerase를 혼합하고 증류수를 더하여 50 uL로 조정 후 94도 5분 1cycle/94도 30초/52도 30초(TRP-1), 53도 30초(TRP-2, Mu-tyr)/72도 30초 35 cycle 증폭, 72도에서 5분간 반응하는 조건으로 수행하였다. 생성된 TRP-1, TRP-2 및 Mu-tyr의 발현억제율은 아래식에 따라 계산하였으며 대조구로는 시료를 처리하지 않은 정상 B16F10세포를 사용하였다.
B16F10 cells were inoculated in DMEM medium with 10% FBS at a concentration of 5 × 10 5 and incubated in 37 ° C., 5% CO 2 incubator for 24 hours. Incubated for 24 hours, the diluted alpha lipoic acid cosmetic composition prepared in Example 3 was diluted to dimethyl sulfoxide to 50 and 100 µg / ml, respectively, and incubated under the same conditions for 18 hours. Thereafter, B16F10 cells were recovered using Trizol reagent (invitrogen, USA), mRNA was extracted, and cDNA was synthesized through a series of processes. From the synthesized cDNA, TRP-1 (Tyrosinase related protein-1), TRP-2 (Tyrosinase related protein-2) and Mu-tyrosinase gene regions were amplified to confirm the expression level of the gene by electrophoresis. (GenePro, Hangzhou bioer tech., CHINA) using 10x taq polymerase buffer, 10 mM dNTP, 10 pmol primer (TRP-1 F: AGG AAT CTG GCT TGG GAT TT, TRP-1 R: ATG AGC CAC AAG GGT CAG TC, TRP-2 F: AGC AGA CGG AAC ACT GGA CT, TRP-2 R: CAG GTA GGA GCA TGC TAG GC, Mu-tyr F: GGG CCC AAA TTG TAC AGA GA, Mu-tyr R: GGC AAA TCC TTC CAG TGT GT), taq polymerase was mixed and distilled water was adjusted to 50 uL, then 94 ° 5 min 1 cycle / 94 ° 30 sec / 52 ° 30 sec (TRP-1), 53 ° 30 sec (TRP-2, Mu- tyr) / 72 degrees 30 seconds 35 cycles amplification, was carried out under the conditions for 5 minutes reaction at 72 degrees. The expression inhibition rate of the generated TRP-1, TRP-2 and Mu-tyr was calculated according to the following equation, and the control group used normal B16F10 cells without treatment.

발현억제율(%) = {1-(B/A)} × 100(%)Expression inhibition rate (%) = {1- (B / A)} × 100 (%)

A: 상기 대조군에서의 TRP-1, TRP-2 및 Mu-tyr 발현 량A: the amount of TRP-1, TRP-2 and Mu-tyr expression in the control group

B: 시료 처리 및 B16F10세포의 TRP-1, TRP-2 및 Mu-tyr 발현 량
B: Sample Processing and TRP-1, TRP-2 and Mu-tyr Expression in B16F10 Cells

상기 시험결과 하기의 표 7과 같은 결과를 얻었다.The test results were obtained as shown in Table 7 below.

시료
농도
(㎍/㎖)
sample
density
(Μg / ml)
발현억제율(%)Expression inhibition rate (%)
TRP-1TRP-1 TRP-2TRP-2 Mu-tyrMu-tyr 실시예 3
화장료
Example 3
Cosmetics
비교예 5
화장료
Comparative Example 5
Cosmetics
실시예 3
화장료
Example 3
Cosmetics
비교예 5
화장료
Comparative Example 5
Cosmetics
실시예 3
화장료
Example 3
Cosmetics
비교예 5
화장료
Comparative Example 5
Cosmetics
00 0.000.00 0.000.00 0.000.00 0.000.00 0.000.00 0.000.00 5050 0.000.00 0.000.00 0.000.00 0.000.00 0.000.00 0.000.00 100100 19.7019.70 13.0513.05 41.6841.68 28.6428.64 16.8116.81 11.2111.21

상기 표 7의 결과에서 확인되는 바와 같이, 실시예 3의 안정성이 증진된 알파 리포산 화장료 조성물을 적용한 경우가 적용하지 않은 경우보다 멜라닌 합성에 관여하는 유전자인 TRP-1, TRP-2 및 Mu-tyr의 발현을 억제하였으며, 농도가 증가할수록 보다 우수한 효과를 보여주었다. 또한 상기 표 7에서 확인되는 바와 같이 흰목이버섯추출물을 함유하지 않는 비교예 5의 화장료조성물에 비하여 훨씬 우수한 효과를 나타내었다. As confirmed in the results of Table 7, TRP-1, TRP-2, and Mu-tyr, which are genes involved in melanin synthesis, were not applied when the alpha lipoic acid cosmetic composition with enhanced stability of Example 3 was not applied. The expression of was suppressed and showed a better effect as the concentration was increased. In addition, as confirmed in Table 7, the white neck showed a much better effect than the cosmetic composition of Comparative Example 5 containing no mushroom extract.

시험예 5: 세포독성시험Test Example 5: Cytotoxicity Test

섬유아세포를 10% FBS를 첨가한 IMDM 배지에 5×105의 세포농도로 접종하여 37℃, 5% CO2배양기에서 24시간 동안 배양하였다. 배양 후 배지를 제거하고 상기 실시예 3의 안정성이 증진된 알파 리포산 화장료 조성물을 최종 농도가 50, 100, 500, 1000㎍/㎖가 되도록 디메틸설폭시드에 희석하여 제조한 희석용액을 처리하여 24시간 배양한 후에 MTT(3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium boromide, Sigma, U.S.A.)용액을 각 well에 100㎕씩 첨가한 후(3㎎/㎖) 4시간 동안 더 배양하였다. 이후 상층액을 제거하고, 150㎕의 디메틸설폭시드를 첨가한 후, 30분간 shaking하여 생성된 formazan을 녹여 multimicroplate reader(Molecular device Spectra max190)를 이용하여 540nm에서 흡광도를 측정하였다. 세포생존율은 아래의 식에 따라 계산하였으며 그 결과는 하기의 표 8에 나타내었다.
Fibroblasts were inoculated in IMDM medium with 10% FBS at a cell concentration of 5 × 10 5 and incubated for 24 hours in a 37 ° C., 5% CO 2 incubator. After incubation, the medium was removed, and the diluted lipoic acid cosmetic composition having enhanced stability of Example 3 was treated with a diluting solution prepared by diluting the dimethyl sulfoxide to a final concentration of 50, 100, 500, and 1000 µg / ml for 24 hours. After incubation, 100 μl of MTT (3- [4,5-dimethylthiazol-2yl] -2,5-diphenyltetrazolium boromide, Sigma, USA) solution was added to each well (3 mg / ml) and further incubated for 4 hours. It was. Then, the supernatant was removed, 150 μl of dimethyl sulfoxide was added, and the generated formazan was dissolved by shaking for 30 minutes, and the absorbance was measured at 540 nm using a multimicroplate reader (Molecular device Spectra max190). Cell viability was calculated according to the following formula and the results are shown in Table 8 below.

세포 생존율(%)=시료첨가군의 흡광도 / 대조군의 흡광도 × 100
Cell viability (%) = absorbance of the sample addition group / absorbance of the control group × 100

시료 농도(㎍/㎖)Sample concentration (µg / mL) 세포 생존율(%)Cell survival rate (%) ConCon 100100 6.256.25 100100 12.512.5 95.9795.97 2525 91.9491.94 5050 88.1788.17 100100 80.9780.97

상기 표 8의 결과에서 보는 바와 같이, 실시예 3의 안정성이 증진된 알파 리포산 화장료 조성물을 적용한 시료 모두 6.25㎍/㎖ 농도에서 세포 독성이 없는 것으로 확인되었고, 사용 농도가 100㎍/㎖에서는 세포 생존율이 감소하였으나 안전에는 문제가 없는 것을 확인하였다.
As shown in the results of Table 8, all of the samples to which the alpha-lipoic acid cosmetic composition with enhanced stability of Example 3 was applied were found to have no cytotoxicity at the concentration of 6.25 µg / ml, and the cell viability at the concentration of 100 µg / ml. Although this decreases, it is confirmed that there is no problem in safety.

Claims (4)

(A)용매인 물에 포접체인 하드록시프로필 베타 사이클로덱스트린(Hydroxypropyl β-Cyclodextrin)을 넣은 후 60~80℃에서 중탕가온하여 용해시켜 혼합하는 단계;
(B)상기 (A)단계의 혼합물에 알파 리포산을 50~60℃의 조건 하에서 투입하여 혼합하는 단계;
(C)흰목이버섯추출물을 상기 (B)단계의 혼합물에 추가하여 혼합하는 단계; 및
(D)상기 (C)단계의 혼합물을 pH 7.0 ~ 9.0으로 보정하는 단계를 포함하여 이루어지며,
상기 하드록시프로필 베타 사이클로덱스트린(Hydroxypropyl β-Cyclodextrin)은 20 ~ 80 중량%, 상기 알파 리포산은 1.0~10.0중량%, 상기 흰목이버섯추출물은 0.01 ~ 3.0 중량%, 물은 잔량으로서 첨가됨을 특징으로 하는 알파리포산의 안정화방법.
(A) adding a hydroxypropyl beta cyclodextrin (Hydroxypropyl β-Cyclodextrin) as a clathrate in water as a solvent, followed by dissolving by mixing in warm water at 60 ~ 80 ℃;
(B) adding alpha lipoic acid to the mixture of step (A) under 50 to 60 ° C. and mixing the mixture;
(C) mixing the cedar mushroom extract in addition to the mixture of step (B); And
(D) comprising the step of calibrating the mixture of step (C) to pH 7.0 ~ 9.0,
The hardoxypropyl beta cyclodextrin (Hydroxypropyl β-Cyclodextrin) is 20 to 80% by weight, the alpha lipoic acid is 1.0 to 10.0% by weight, the white fungi extract is 0.01 to 3.0% by weight, water is added as a balance How to stabilize the alpha lipoic acid.
삭제delete 삭제delete 삭제delete
KR1020120001694A 2012-01-05 2012-01-05 Method for stabilizing alpha-lipoic acid Expired - Fee Related KR101196096B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020120001694A KR101196096B1 (en) 2012-01-05 2012-01-05 Method for stabilizing alpha-lipoic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120001694A KR101196096B1 (en) 2012-01-05 2012-01-05 Method for stabilizing alpha-lipoic acid

Publications (1)

Publication Number Publication Date
KR101196096B1 true KR101196096B1 (en) 2012-11-01

Family

ID=47563712

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020120001694A Expired - Fee Related KR101196096B1 (en) 2012-01-05 2012-01-05 Method for stabilizing alpha-lipoic acid

Country Status (1)

Country Link
KR (1) KR101196096B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015105249A (en) * 2013-11-29 2015-06-08 富士フイルム株式会社 Cosmetics
CN117838563A (en) * 2024-01-09 2024-04-09 杭州悦萱堂化妆品有限公司 An anti-sugar complex and an anti-sugar cosmetic composition and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100553157B1 (en) * 2003-10-27 2007-04-12 엔프라니 주식회사 Compositions comprising stabilized resveratrol, alpha-lipoic acid or mixtures thereof, methods for their preparation, and cosmetic compositions containing them
JP2008127341A (en) * 2006-11-22 2008-06-05 Nippon Fine Chem Co Ltd Hydrolyzate of water-soluble polysaccharide derived from white jellyfish, antioxidant containing the same, cosmetic or skin external preparation, food

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100553157B1 (en) * 2003-10-27 2007-04-12 엔프라니 주식회사 Compositions comprising stabilized resveratrol, alpha-lipoic acid or mixtures thereof, methods for their preparation, and cosmetic compositions containing them
JP2008127341A (en) * 2006-11-22 2008-06-05 Nippon Fine Chem Co Ltd Hydrolyzate of water-soluble polysaccharide derived from white jellyfish, antioxidant containing the same, cosmetic or skin external preparation, food

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015105249A (en) * 2013-11-29 2015-06-08 富士フイルム株式会社 Cosmetics
CN117838563A (en) * 2024-01-09 2024-04-09 杭州悦萱堂化妆品有限公司 An anti-sugar complex and an anti-sugar cosmetic composition and preparation method thereof

Similar Documents

Publication Publication Date Title
Gandia-Herrero et al. Stabilization of the bioactive pigment of Opuntia fruits through maltodextrin encapsulation
US20120083460A1 (en) Readily water-soluble isoquercitrin composition
US8658692B2 (en) Method of preparation an inclusion-complex comprising hydrophobic physiological activation material including with cyclodextrin and its use
US20110318397A1 (en) Method for preparing high purity ginsenoside rd using lactobacillus casei and cosmetic composition for anti-wrinkle comprising the high purity ginsenoside rd
KR101544176B1 (en) Stabilizing method for skin whitening, anti-wrinkle, anti-inflammatory and anti-oxidant activity of Dendropanax Morbifera Nakai Extracts from Jeju island and cosmetic composition containing the same
JP5072369B2 (en) Stem cell growth factor expression increase inhibitor and basic fibroblast growth factor expression increase inhibitor
US20110318398A1 (en) Cosmetic composition comprising molecular encapsulated fermented extract of rhus javanica l. as an active ingredient
CN110251421B (en) Cyclodextrin inclusion compound as active agent containing protamine and its prepn and application
KR101196096B1 (en) Method for stabilizing alpha-lipoic acid
KR102425562B1 (en) Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom
KR101833018B1 (en) Cosmetic composition for stabilizing vitamin c containing aronia extract
EP3302409B1 (en) Process and composition for stimulating hyaluronic acid synthesis
US20120015090A1 (en) Readily water-soluble myricitrin composition
KR101525090B1 (en) Cosmetic Composition for skin Whitening
KR20100054379A (en) Rutin inclusion complex, a preparation method thereof, and a cosmetic composition for antiaging comprising the same
KR102157002B1 (en) Composition for Improving Skin Wrinkles and Skin-lightening Using an Extract of Ampelocissus polythyrsa
JP2013075860A (en) Methylmercaptan formation inhibitor
KR101551240B1 (en) Cosmetic Composition for Skin Whitening Having Kaempferia Parviflora
JP5716309B2 (en) Cell activator, hair follicle epithelial cell growth promoter and hair restorer
KR101652455B1 (en) Water soluble Isoflavone with a long-term stability and high-isoflavone-content and preparation method of the same
KR101794343B1 (en) Method for culture product of adenium obesum callus, culture product of adenium obesum callus, and cosmetic composition comprising the same
KR20170013588A (en) Composition for skin whitening and anti-wrinkle comprising Cistanche deserticola extract as effective component
JP4726505B2 (en) External preparation for skin and skin whitening method
KR20140130401A (en) A method of preparing extract improving anti-oxidative activity
JP7115778B2 (en) Melanin production inhibitory composition

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20120105

PA0201 Request for examination
A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20120215

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

Patent event date: 20120105

Patent event code: PA03021R01I

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120527

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20121017

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20121024

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20121024

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20150824

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20150824

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20161117

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20161117

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20170728

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20170728

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20180927

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20180927

Start annual number: 7

End annual number: 7

PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20200804